Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.
Citations
2,025 citations
1,895 citations
1,684 citations
952 citations
Cites background from "Cancer regression and neurological ..."
...MAGE-A3 may be a particularly difficult target because another group using an independently derived TCR that was specific for MAGE-A3 peptides presented on HLAA*02 has reported severe on-target off-tumor toxicity.(25) In that study, neurologic toxicity was observed because of the unexpected expression of other members of the MAGE cancer-testis family in the central nervous system....
[...]
942 citations
Cites background from "Cancer regression and neurological ..."
...This toxicity has not been documented in clinical trials ofCARs, but it has been observed in clinical trials of T cells genetically modified to express T-cell receptors.(33,52,53)...
[...]
References
14,926 citations
5,250 citations
3,497 citations
3,204 citations
2,614 citations
Additional excerpts
...ESO-1 TCR, ALVAC, IL-2 41 1 PR (5) None...
[...]